Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the Milestone Pharmaceuticals fourth quarter and year-end 2025 corporate update conference call. At this time, all participants are in listen-only mode. After the speaker's remarks, there will be a question-and-answer session. As a reminder, this conference is being recorded. I will now turn the call over to your host, Michael Wood of LifeSite Advisors. You may now begin your conference. Thank you, Operator. Good morning. Good morning, everyone. and welcome to the Milestone Pharmaceuticals full year 2025 financial results and business update conference call. Earlier this morning, the company issued a press release providing an overview of its financial results for the year ended December 31, 2025, and recent corporate highlights. The release can be accessed on the investors' media section of the company's website, milestonepharma.com. Before I begin, I'd like to remind everyone that some of the information presented on this conference call contains forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause actual clinical programs, future results, progress, timing, performances, or achievements to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties associated with milestones, business, and factors could cause or contribute to such differences are described in detail in the company's filings with the SEC, including in the risk factor section of the earnings report on Form 10-K for the year ended December 31, 2025, filed with the SEC today. Speaking on the call this morning will be Joseph Oliveto, President and Chief Executive Officer, Lorenz Muller, Chief Commercial O...